117 related articles for article (PubMed ID: 37000082)
21. Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.
Wang H; Dong Q; Fu R; Qu W; Ruan E; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Shao Z
Biomed Res Int; 2015; 2015():597293. PubMed ID: 25861635
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
Liu X; Bai Y; Wang T; Song Y; Sun F; Xia R; Zhu F; Ma J; Lu Q; Ye X; Zhan X; Li L; Guo X; Cheng S; Li Y; Guo Z; Chen Y; Qian S; Qin L; Zhang Q; Cao S; Yang R
Platelets; 2023 Dec; 34(1):2157806. PubMed ID: 36597010
[TBL] [Abstract][Full Text] [Related]
23. Effect of recombinant human thrombopoietin on IL-2, IL-4 and platelet parameters in thrombocytopenic purpura.
Zhao M; Liang X; Chen C; Du X; Dang X
Cell Mol Biol (Noisy-le-grand); 2023 May; 69(5):119-125. PubMed ID: 37571891
[TBL] [Abstract][Full Text] [Related]
24. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial.
Han TT; Xu LP; Liu DH; Liu KY; Wang FR; Wang Y; Yan CH; Chen YH; Sun YQ; Ji Y; Wang JZ; Zhang XH; Huang XJ
Ann Hematol; 2015 Jan; 94(1):117-28. PubMed ID: 25069650
[TBL] [Abstract][Full Text] [Related]
26. [Clinical tolerance test of recombinant human thrombopoietin].
Zhao Y; Jiang J; Jiao L
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1508-11. PubMed ID: 16200777
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Analysis of Recombinant Human Thrombopoietin for Treatment of 46 Adult Patients with Newly Diagnosed Primary Immune Thrombocytopenia].
Wang M; Liu YF; Sun H; Xie XS; Ma J; Gan SL; Dong YJ; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):531-5. PubMed ID: 27151024
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis.
Wang Y; Wang Z; Wu L; Zhang J; Wang J; Yan L
Ann Hematol; 2013 Dec; 92(12):1695-9. PubMed ID: 23778995
[TBL] [Abstract][Full Text] [Related]
29. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
[TBL] [Abstract][Full Text] [Related]
30. [Impact of recombinant human thrombopoietin (rhTPO) on short-term response of immunosuppressive therapy in patients with newly diagnosed acquired severe aplastic anemia].
Zhang L; Yang W; Ye L; Zhou K; Jing L; Li Y; Li Y; Li J; Peng G; Song L; Zhao X; Wu Z; Zhang F
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):181-5. PubMed ID: 25854458
[TBL] [Abstract][Full Text] [Related]
31. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study.
Mo H; Liu P; Qin Y; He X; Han X; Yao J; Su W; Zhang S; Tang L; Zhao F; Gui L; Yang S; Yang J; Zhou S; Zhang Z; Shi Y
Chronic Dis Transl Med; 2021 Sep; 7(3):190-198. PubMed ID: 34505019
[TBL] [Abstract][Full Text] [Related]
33. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients.
Mei H; Xu M; Yuan G; Zhu F; Guo J; Huang R; Qin J; Lv T; Qin F; Cai H; Yin P; Qin T; Hu Y
Br J Haematol; 2021 Dec; 195(5):781-789. PubMed ID: 34528239
[TBL] [Abstract][Full Text] [Related]
34. A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation.
Sun YQ; Kong Y; Zhang XH; Wang Y; Shi MM; Song Y; Kong J; Fu HX; Yan CH; Xu LP; Liu KY; Huang XJ
Platelets; 2019; 30(8):994-1000. PubMed ID: 30569802
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Wu M; Ma IX; Xie YH; Ye XJ; He HS; Hua JS; Yang RY; Wang XH; Wang XQ; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1991-1997. PubMed ID: 33283731
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
[TBL] [Abstract][Full Text] [Related]
37. [Clinical use of recombinant human thrombopoietin. Status and perspectives].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2001 May; 163(19):2659-62. PubMed ID: 11360368
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia.
Dou L; Xu Q; Wang M; Xiao Y; Cheng L; Li H; Huang W; Mei J; Jing Y; Bo J; Liu D; Yu L
Onco Targets Ther; 2019; 12():5013-5023. PubMed ID: 31303761
[No Abstract] [Full Text] [Related]
39. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
